共 4 条
[1]
Battelino T(2022)Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Lancet Diabetes Endocrinol 17 364-377
[2]
Gastaldelli A(2022)Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Lancet Diabetes Endocrinol. undefined undefined-undefined
[3]
Heise T(2022)Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Lancet Diabetes Endocrinol. undefined undefined-undefined
[4]
Perreault L(2021)Novel therapies with precision mechanisms for type 2 diabetes mellitus Nat Rev Endocrinol undefined undefined-undefined